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pThe human immunodeficiency virus type 1 (HIV-1) en-
odes a transcriptional transactivator called Tat (hTat)
Cullen, 1998; Emerman and Malim, 1998; Frankel and
oung, 1998; Gait and Karn, 1995; Gaynor, 1995; Jeang,
998; Jones, 1997; Jones and Peterlin, 1994). hTat is
xpressed early in the life cycle of HIV-1 and is essential
or viral gene expression, replication, and pathogenesis
Dayton et al., 1986; Fisher et al., 1986). Unlike other
nown eukaryotic transcriptional activators that bind to
NA, hTat interacts with the transactivation response
TAR; hTAR) RNA structure, which is located at the 59 end
f all viral transcripts. Moreover, hTat regulates the pro-
ess of elongation rather than initiation of transcription
Jones and Peterlin, 1994; Kao et al., 1987). In its absence,
ranscription complexes assemble on the viral promoter
LTR), but RNA polymerase II (RNAPII) synthesizes only
hort transcripts (Kao et al., 1987). The binding of hTat to
TAR renders the RNAPII competent for elongation (Kao
t al., 1987; Laspia et al., 1989; Feinberg et al., 1991). This
igh affinity interaction between hTat and hTAR is medi-
ted by the cyclin subunit of the positive elongation
actor b (P-TEFb). By interacting with the human cyclin T1
hT1), hTat recruits the cyclin-dependent kinase 9
CDK9), which phosphorylates the C-terminal domain
CTD) of RNAPII. The conversion of RNAPII from its
nphosphorylated (RNAPIIa) to phosphorylated (RNA-
IIo) forms marks the transition from initiation to elonga-
ion of transcription (Jones, 1997).
This review begins with structures of hTat and hTAR.
ext, we present genetic and biochemical evidence that
ed to the current model of hTat transactivation. After a
iscussion of other lentiviral Tat proteins, which recruit
-TEFb by slightly different mechanisms, Tat transactiva-
ion is placed into the context of eukaryotic transcription.
1 To whom reprint requests should be addressed at Mt. Zion–UCSF
ox 0703, 3rd and Parnassus Avenues, San Francisco, CA 94143-0703.sax: (415) 502-1901. E-mail: matija@itsa.ucsf.edu.
245tructure of hTat
hTat is translated from multiply spliced viral transcripts
hat do not require the regulator of viral gene expression
Rev) for their export from the nucleus to the cytoplasm
Jones and Peterlin, 1994). It is encoded by two exons
hat flank the env gene and code for 72 and 14–29
esidues, respectively (Jones and Peterlin, 1994). Thus
epending on the viral isolate, hTat contains 86–101
esidues. In some strains of HIV-1, the function of hTat is
lso contained in Tev (Benko et al., 1990). Tev includes
he first exon of tat, 114 nucleotides from env, and the
econd exon of rev.
Five conserved regions have been identified in hTat
Jones and Peterlin, 1994). They form the N-terminal,
ysteine-rich, core, basic, and C-terminal domains (Fig.
). The N-terminal, cysteine-rich and core sequences
lso represent the activation domain (AD), where six of
even cysteines are indispensable for function (Garcia et
l., 1988; Rice and Carlotti, 1990). Divalent cations, espe-
ially Zn21, are required for the folding of hTat and for
nteractions between hTat and its coactivator (Garber et
l., 1998; Jones, 1997). The C-terminal arginine-rich motif
ARM) in hTat binds to hTAR in vitro (Dingwall et al., 1989;
oy et al., 1990a; Weeks, 1990) (Fig. 1). Changing all
xcept one arginine to lysines is sufficient for the func-
ion of the ARM (Siomi et al., 1990), which also serves as
nuclear localization signal (Hauber et al., 1989; Ruben
t al., 1989; Siomi et al., 1990).
The N-terminal 47 residues (AD) in hTat are function-
lly autonomous and can be linked to heterologous RNA-
r DNA-binding proteins. Chimeras between hTat and
he coat protein of bacteriophage MS2/R17 or Rev acti-
ate the HIV-1 LTR via their respective operator or Rev
esponse element (RRE) RNA targets (Madore and
ullen, 1995; Selby and Peterlin, 1990; Southgate et al.,
990; Tiley et al., 1992). Hybrid Tat-Gal4 or Tat-LexA
roteins also function via their respective DNA-binding
ites (Berkhout et al., 1990; Kamine et al., 1991; Southgate
0042-6822/99 $30.00
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246 MINIREVIEWnd Green, 1991). However, the mode of action of hTat
ia RNA and DNA appears to be different (Pessler and
ernandez, 1998). Additionally, the expression of the AD
nterferes with the function of hTat in cells (Gaynor, 1995).
n sharp contrast, the ARM in hTat cannot be moved
way from the AD for productive interactions between
Tat and hTAR (Luo et al., 1993). Thus the RNA-binding
omain in hTat is not functionally autonomous.
tructure of hTAR
hTAR forms an RNA stem-loop of 59 nucleotides
Jones and Peterlin, 1994). However, a shorter structure
rom positions 119 to 142 is sufficient for hTat transac-
ivation (Feng, 1988; Selby et al., 1989) (Fig. 1). Between
ositions 123 to 125 and 130 to 135 are located a 59
-rich bulge (59 bulge) and a central hexanucleotide
pical loop (central loop), respectively (Fig. 1). Although
ompensatory mutations in the stem are tolerated, se-
uences in the 59 bulge and central loop are essential for
Tat transactivation (Garcia et al., 1988; Dingwall et al.,
989; Selby et al., 1989; Berkhout et al., 1990; Roy et al.,
990a,b).
hTat binds to U23, which is the first nucleotide in the
ulge. A27 • U38 above the 59 bulge and two phosphates
ocated between A22, U23 and C24 contribute to this
inding (Calnan et al., 1991; Weeks and Crothers, 1991;
ao and Frankel, 1992; Churcher et al., 1993). These
FIG. 1. Structure of Tat and TAR from HIV-1 (hTat and hTAR). hTat
easures 86–101 residues. Presented are contiguous AD and RNA-
inding domains (ARM). The former consists of cysteine-rich and core
equences, which bind to the cellular coactivator of Tat. The ARM also
epresents its nuclear localization signal (NLS). Eight basic residues
ind to the 59 bulge (U23) in TAR. Additional residues in TAR also
ontribute to this binding. These are A27 • U38 above the 59 bulge and
wo phosphates between A22, U23, and C24. The cellular coactivator of
at binds to the central loop. Together, these proteins create a high-
ffinity RNA-binding complex and activate viral transcription. Presented
re nucleotides from positions 21–41 in hTAR.nteractions are stabilized further by hydrogen bonds in the major groove of RNA (Frankel and Kim, 1991; Frankel,
992a,b; Gait and Karn, 1993; Gait and Karn, 1995). The
ore domain in hTat also contributes to the specificity
nd affinity of these interactions (Churcher et al., 1993).
n the absence of hTat, stacking interactions within the
tem disorder the helical structure of hTAR. After the
ddition of hTat, nucleotides in the 59 bulge become
eparated so that U23 and A27 • U38 form a base-triple
hat stabilizes hydrogen bonding of the arginine to G26
nd phosphates between A22, U23, and C24. This struc-
ure has been called the “arginine fork” (Puglisi et al.,
992, 1993).
-TEFb mediates hTat transactivation
Although hTat binds to the 59 bulge, the central loop in
TAR is also required for hTat transactivation in cells.
oreover, the two structures cannot be moved with re-
pect to each other (Garcia-Martinez et al., 1995). Addi-
ionally, studies using TAR decoys (Marciniak et al., 1990;
ohjanen et al., 1997; Lee et al., 1995) and squelching
etween different lentiviral Tat proteins (Carroll et al.,
992; Madore and Cullen, 1993), both of which inhibit Tat
ransactivation, suggested that a cellular protein is re-
uired for the productive interaction between hTat and
TAR in vivo (Jones and Peterlin, 1994). This idea gained
urther support from the rescue of hTat transactivation
which functions poorly in rodent cells) in somatic cell
ybrids between human and rodent cells, or in rodent
ells that contain the human chromosome 12 (Hart et al.,
991, 1993; Alonso et al., 1992, 1994).
The protein that fulfills all of the above biochemical
nd genetic criteria is hT1, which together with CDK9
orms P-TEFb (Mancebo et al., 1997; Zhu et al., 1997;
eng et al., 1998; Wei et al., 1998). That the AD of hTat
nteracts with a serine/threonine kinase was first sug-
ested by the isolation of the Tat-associated kinase (TAK)
y hTat-affinity chromatography (Herrmann, 1993; Herr-
ann et al., 1996; Yang et al., 1996). TAK also phosphor-
lated the CTD of RNAPII and was inhibited by a purine
ucleoside analog 5,6-dicloro-1-b-D-ribofuranosylben-
imidazole (DRB) (Herrmann and Rice, 1995). Further
iochemical analysis revealed that TAK is P-TEFb (Man-
ebo et al., 1997; Zhu et al., 1997). In P-TEFb, hTat binds
o hT1, and the formation of the tripartite complex be-
ween hTat, hT1, and hTAR depends on the 59 bulge and
entral loop in TAR (Wei et al., 1998; Garber et al., 1998;
ieniasz et al., 1998; Fujinaga et al., 1999; Ivanov et al.,
999; Kwak et al., 1999). Moreover, overexpression of hT1
n rodent cells rescues hTat transactivation (Wei et al.,
998; Garber et al., 1998; Bieniasz et al., 1998; Fujinaga et
l., 1999; Ivanov et al., 1999; Kwak et al., 1999) and
upports full HIV-1 replication when introduced into Chi-
ese hamster cells expressing the appropriate co-recep-
ors (Wimmer et al., 1999). However, differences in post-
ranscriptional processing of viral transcripts represent
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247MINIREVIEWdditional obstacles toward the creation of a mouse
odel of AIDS (Garber et al., 1998).
The model that emerges from these studies is pre-
ented in Fig. 2. After the synthesis of hTAR, hTat recruits
-TEFb to the HIV-1 LTR. hT1 increases the affinity and
pecificity of the binding of hTat to hTAR (Wei et al., 1998).
oreover, this RNA–protein interaction depends on the
resence of Zn21 (Garber et al., 1998). CDK9 then phos-
horylates the CTD of RNAPII, which leads to the elon-
ation of viral transcription.
The first 272 residues of hT1 are sufficient for hTat
ransactivation (Wei et al., 1998; Garber et al., 1998;
ieniasz et al., 1998, 1999b; Ivanov et al., 1999; Kwak et
l., 1999). In this region, residues from positions 250 and
65 represent the Tat-TAR recognition motif (TRM) (Gar-
er et al., 1998). TRM is required but is not sufficient for
he formation of the tripartite complex between hTat, hT1,
nd hTAR. N-terminal residues in the cyclin box of hT1
re also essential. A reciprocal exchange of a cysteine to
tyrosine at position 261 (C2613Y261, Fig. 3) between
T1 and the murine cyclin T1 (mT1) renders hT1 inactive
nd mT1 active for hTat transactivation (Garber et al.,
998; Bieniasz et al., 1998; Fujinaga et al., 1999; Ivanov et
l., 1999; Kwak et al., 1999). C261 joins other basic resi-
ues in the TRM of hT1, which are required for the
nteraction between hTat and hTAR (Garber et al., 1998;
ieniasz et al., 1998; Fujinaga et al., 1999; Ivanov et al.,
999; Kwak et al., 1999) (Fig 3).
The identification of a minimal functional domain in hT1
ight facilitate structural studies of hTat and hT1 bound to
TAR. At the present, some predictions can be made, but
hey rely on the superimposition of the sequence of hT1
nto the known crystal structure of cyclin H (Fig. 4). The
hree-dimensional structure of the cyclin box consists of
wo repeats, each containing five a-helices (Andersen et al.,
997). As revealed from the structure of the cyclin A–CDK2
FIG. 2. The role of P-TEFb in hTat transactivation. After the synthesis o
hosphorylates the CTD of RNA polymerase II (RNAPIIo), which leads t
here the recruitment of P-TEFb is not understood, the interaction bet
ubstrate of P-TEFb is a partially phosphorylated CTD.air (Jeffrey et al., 1995), CDK9 should bind to a large gurface in hT1, which encompasses both repeats of the
yclin box. Moreover, the specificity for these cyclins T1
hould be provided by two additional N- and C-terminal
-helices (Morgan, 1997). In cyclin H, these a-helices pack
ogether against the first repeat on the side opposite to the
nterface that binds to the kinase. C261 in human cyclin T1
its into this C-terminal a-helix, where it is exposed to the
urround (Fig. 4).
at proteins and TAR elements from other
entiviruses
Lentiviral Tat proteins share N-terminal activation do-
ains and C-terminal ARMs. Tat proteins from HIV-2/
, preformed complexes of hTat and P-TEFb are recruited to hTAR. CDK9
fficient elongation of viral transcription. In contrast to other promoters,
Tat and hTAR brings CDK9 to the proximity of the CTD. The preferred
FIG. 3. A cysteine-to-tyrosine substitution found in the murine cyclin
1 (mT1) blocks the formation of the tripartite complex between hTat,
uman cyclin T1 (hT1) and hTAR. hT1 binds to hTat. This results in
ncreased binding of hTat to hTAR. On the other hand, the binding
etween hTat and mT1 is weaker and does not support the formation
f the higher order complex with hTAR. C261 in hT1, which is Y261 in
T1, is critical for the formation of the tripartite complex between hTat,
T1, and hTAR. This single point mutation represents the strongestf hTAR
o the e
ween henetic evidence that hT1 is the coactivator of hTat.
s
f
v
r
1
c
i
(
1
1
a
2
1
5
b
s
a
c
f
t
h
c
t
r
t
e
b
a
B
i
o
a
l
(
f
b
t
e
s
c
f
T
(
p
r
b
a
t
L
f
b
248 MINIREVIEWimian immunodeficiency virus (sTat), bovine immunode-
iciency virus (BIV) (bTat), and equine infectious anemia
irus (EIAV) (eTat) contain 130, 108, and 75 residues,
espectively (Pallansch et al., 1992; Jones and Peterlin,
994). However, eTat contains only two cysteines in its
ysteine-rich region. TAR elements from HIV-2/simian
FIG. 4. The hypothetical structure of hT1 derived from the crystal
tructure of cyclin H. Two repeats of five a-helices form the conserved
yclin box (blue). The N- and C-terminal a-helices, which are important
or the specificity of cyclins, are depicted yellow and red, respectively.
hey are located opposite of the proposed kinase-binding domain
green), which was derived from the structure of the CDK2–cyclin A
air. C261 (orange) in hT1 is found in the C-terminal a-helix. Further
esidues, which contribute to the formation of the tripartite complex
etween hTat, hT1, and hTAR, are in close proximity to the C-terminal
-helix. The figure was generated using MOLSCRIPT (Kraulis, 1991).
FIG. 5. Interactions between different lentiviral Tat proteins and their
o the 59 bulge and central loop on hTAR. For EIAV, equine cyclin T1 (e
29 is required for the formation of the tripartite complex between eTa
rom BIV (bTAR) without the requirement of the central loop. Because b
inding of bTat to bTAR.mmunodeficiency virus (sTAR), EIAV (eTAR), and BIV
bTAR) also differ from those of HIV-1 (Pallansch et al.,
992; Jones and Peterlin, 1994). Although sTAR contains
23 nucleotides, which form duplicated stem-loops that
re linked by a short stem, eTAR and bTAR contain only
5 and 28 nucleotides, respectively (Chen and Frankel,
994; Jones and Peterlin, 1994). In addition, eTAR lacks a
9 bulge (Fig. 5).
Functional differences in Tat transactivation have also
een noted. For example, although hTat is fully active via
TAR, sTat functions only partially via hTAR (Emerman et
l., 1987). Likewise, eTat cannot activate eTAR in human
ells (Derse, 1991; Derse et al., 1991). In contrast, bTat
unctions via bTAR or hTAR in any cell type. Coupled with
he previous observation that hTat functions poorly via
TAR in rodent cells, these findings suggest that spe-
ies-specific cyclins T1 also could play important roles in
hese other lentiviral systems.
Indeed, equine and canine cyclins T1 (eT1 and cT1)
escue eTat transactivation in human cells and support
he binding of eTat to eTAR (Bieniasz et al., 1999b; Taube
t al., 1999). Moreover, hT1 facilitates the interaction
etween sTat and sTAR (Bieniasz et al., 1999a), whereas
ny cyclin T1 can function with bTat on the BIV LTR (M.
arboric and B. M. Peterlin, unpublished data). Interest-
ngly, although hT1 and eT1 bind to eTat equivalently,
nly eT1 supports its interaction with eTAR (Bieniasz et
l., 1999b; Taube et al., 1999). This restriction maps to a
eucine at position 29 in eT1, which is a valine in hT1
Taube et al., 1999). Because eTat but not hTat contains
our critical leucines, this finding suggests that a leucine
ridge is formed between eTat and eT1, which specifies
he alignment of the ARM of eTat and basic residues in
T1, which then bind to the central loop in eTAR. Because
ements. For HIV-1, a complex of hTat and hT1 is preformed and binds
ports the binding of eTat to TAR for EIAV (eTAR). Together with C261,
nd eTAR. In contrast, Tat from BIV (bTat) binds to the 59 bulge in TAR
ctions in any cell type, we propose that any cyclin T1 can support theTAR el
T1) sup
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249MINIREVIEWTat requires a cysteine at position 261 and eTat re-
uires a leucine at position 29 in their respective cyclins
1, Tat proteins most likely contact both N- and C-termi-
al a-helices in cyclins T1 (Bieniasz et al., 1999b; Taube
t al., 1999) (Fig. 5).
at in the context of eukaryotic transcription
Tat has placed the control of elongation of transcrip-
ion at central stage (Fig. 6). On the HIV-1 LTR, transcrip-
ion starts with the assembly of the large, multiprotein
NAPII holoenzyme (Cujec et al., 1997a). General tran-
cription factors (GTFs), primarily TFIID, TFIIB, and TFIII,
osition RNAPII near the start site of transcription (Jones
nd Peterlin, 1994; Cujec et al., 1997a). The CTD of
NAPII, which contains 52 repeats of a heptapeptide
equence (YSPTSPT), is not phosphorylated (Dahmus,
996; Okamoto et al., 1996). In its flexible form, the CTD
s covered by mediators, which also interact with activa-
ors bound to DNA (Jiang et al., 1998). Other transcrip-
ional enhancers, such as NF-kB, NF-AT, and LEF-1, re-
ruit histone acetyltransferases (HATs) such as CBP/
300 and P/CAF, which increase the number of
einitiation events at the promoter (Sheridan et al., 1997).
o this end, it is of interest that Tat can interact with
BP/p300 and P/CAF and possibly affect the chromatin
onformation of the HIV-1 LTR (Benkirane et al., 1998;
ottiger and Nabel, 1998; Marzio et al., 1998). Addition-
lly, Tat contains several lysines, which could be acety-
ated.
The next step is promoter clearance. TFIIH, which
FIG. 6. General scheme of eukaryotic transcription. Preinitiation c
ediators, which bind to the unphosphorylated CTD. In this early step, H
f promoter clearance and CTD phosphorylation (2). A CDK2 pseudosub
hosphorylated (RNAPIIa) and interacts with N-TEFb, which contains th
at, which completes the phosphorylation of the CTD (4) (RNAPIIo). D
longation of transcription. N-TEFb and mediators are replaced by elo
ylation machinery. Productive elongation of transcription follows.ontains DNA helicases and the CDK-activating kinase (CAK), is held on RNAPII by TFIIE (Orphanides et al.,
996; Hampsey and Reinberg, 1999) Helicases open the
ouble-stranded DNA so that it can be copied to RNA
Svejstrup et al., 1996). CDK7, which is the kinase in CAK,
artially phosphorylates the CTD, thus removing some
ediators. This process is required to release RNAPII
rom DNA-bound activators (Zawel et al., 1995; Zawel and
einberg, 1995). Interestingly, Tat can interact with TFIIH
nd increase the activity of CDK7 (Blau et al., 1996;
arada and Roeder, 1996; Cujec et al., 1997b; Garcia-
artinez et al., 1997). A pseudosubstrate of CDK7
mC2p), which contains 20 residues surrounding a thre-
nine at position 160 in CDK2 that is phosphorylated by
AK for the progression of the cell cycle, blocks Tat
ransactivation (Cujec et al., 1997b). This interaction be-
ween Tat and TFIIH might also explain the ability of Tat
o activate transcription when tethered to DNA (South-
ate et al., 1990; Pessler and Hernandez, 1998).
In theory, promoter clearance should suffice for effi-
ient elongation of transcription. However, at this point,
egative transcription elongation factors b (N-TEFb),
hich most likely consist of DRB-sensitivity inducing
actors (DSIF) and negative elongation factors (NELFs),
ind to RNAPII and block its progress (Yamaguchi et al.,
999). Because of the formation of a pause structure,
hich extends slightly beyond hTAR, HIV-1 LTR might be
ore efficient at loading N-TEFb onto RNAPII (Palangat
t al., 1998). By phosphorylating the CTD and possibly
SIF and NELFs, P-TEFb counteracts N-TEFb. Indeed,
omponents of DSIF are required for Tat transactivation
xes are assembled at promoters. They contain RNAPII, GTFs, and
crease rates of reinitiation of transcription (1). TFIIH starts the process
mC2p) blocks the activity of CDK7. At this point, RNAPII is only partially
(SPT4, SPT5) and NELFs (3). P-TEFb is recruited to the HIV-1 LTR by
ATP analog, blocks the activity of CDK9 in P-TEFb and prevents the
s, which include capping enzymes, splicing factors, and the polyade-omple
ATs in
strate (
e DSIF
RB, an
ngatorWu-Baer et al., 1998). The phosphorylation of the CTD
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250 MINIREVIEWlso dissociates N-TEFb from RNAPII (Wada et al., 1998;
amaguchi et al., 1998, 1999). The rigid, more massive
TD now binds to elongators, which include capping
nzymes, splicing factors, and the polyadenylation ma-
hinery (Otero et al., 1999). Thus the elongating RNAPII is
ree of most GTFs except for TFIIF and TFIIS and con-
ains proteins that are required for cotranscriptional pro-
essing (Reines et al., 1996; Shilatifard et al., 1997).
Tat is the first eukaryotic transcriptional activator that
cts via RNA rather than DNA (Jones and Peterlin, 1994;
ait and Karn, 1995; Gaynor, 1995; Jones, 1997; Cullen,
998; Emerman and Malim, 1998; Frankel and Young,
998; Jeang, 1998). Because RNA passes by the CTD for
otranscriptional processing, it is possible that P-TEFb
ethered to RNA rather than DNA remains in the proxim-
ty of the CTD for a longer period of time (Fujinaga et al.,
998; Gold et al., 1998; Bieniasz et al., 1999c). In this
cenario, RNA presentation should be more efficient
han DNA presentation. Thus Tat has elucidated the
ransition from an elongation-incompetent to an elonga-
ion-competent RNAPII.
erspectives
Although the HIV-1 LTR appears unique among pro-
oters in that DNA-bound activators cannot ensure the
opying of the viral genome, there are precedents in
rokaryotic and eukaryotic systems for this type of tran-
criptional control. The antiterminator N binds to the
utB RNA stem-loop to copy lytic genes in bacterio-
hage l (Greenblatt et al., 1993). In the absence of heat
hock, the RNAPII is arrested just 39 to the start site on
he heat shock promoter in Drosophila melanogaster (Lis
nd Wu, 1993). In this organism, other inducible promot-
rs appear to have similar arrested RNAPII complexes
Gilmour and Lis, 1985). In humans, proto-oncogenes
-myc, c-myb, and c-fos are regulated, in part, by tran-
criptional attenuation (Greenblatt et al., 1993). It is pos-
ible that the HIV-1 LTR represents only one extreme of
he spectrum and that cellular homologs of Tat will be
iscovered.
In the case of HIV, the absence of Tat marks one form
f proviral latency, where short transcripts accumulate in
hese cells (Adams et al., 1994). In memory T cells, HIV
an stay dormant for months to years (Finzi et al., 1999).
owever, with cellular activation, replication competent
iruses can be recovered. Because HIV can infect non-
ividing cells where levels of hT1 and P-TEFb are low,
his finding could explain the establishment and mainte-
ance of proviral latency. Only on cellular activation
nd/or proliferation would levels of hT1 and hTat in-
rease sufficiently for productive replication of HIV. Thus
he understanding and manipulation of this aspect of
iral transcription might have important prognostic and
herapeutic implications.ACKNOWLEDGMENTS
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